More patients with early-stage breast cancer may be able to avoid chemotherapy in the future

Women with early-stage breast cancer who had an intermediate risk recurrence score (RS) from a 21-gene expression assay had similar outcomes, regardless of whether they received chemotherapy, a new study has found.